Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. CorMedix Inc shares valued at $14,985 were purchased by Mistry Erin on Oct 31 ’24. At $9.99 per share, Mistry Erin acquired 1,500 shares. The insider’s holdings grew to 52,011 shares worth approximately $0.64 million following the completion of this transaction.
Also, Hurlburt Elizabeth sold 140,027 shares, netting a total of over 1,565,670 in proceeds. Following the sale of shares at $11.18 each, the insider now holds 45,397 shares.
Before that, Hurlburt Elizabeth had added 140,027 shares to its account. In a trade valued at $1,556,416, the Officer bought CorMedix Inc shares for $11.12 each.
As published in their initiating research note from Leerink Partners on March 07, 2025, CorMedix Inc [CRMD] has been an Outperform and the price target has been revised to $18. Analysts at D. Boral Capital started covering the stock with ‘”a Buy”‘ outlook in a report released in mid January. As of August 26, 2024, Rodman & Renshaw has initiated its “Buy” rating for CRMD. Earlier on August 10, 2023, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for CRMD stock.
Analyzing CRMD Stock Performance
During the last five days, there has been a drop of approximately -0.40%. Over the course of the year, CorMedix Inc shares have jumped approximately 52.84%. Shares of the company reached a 52-week high of $13.09 on 01/17/25 and a 52-week low of $5.60 on 04/07/25.
Support And Resistance Levels for CorMedix Inc (CRMD)
According to the 24-hour chart, there is a support level at 12.23, which, if violated, would cause prices to drop to 12.09. In the upper region, resistance lies at 12.63. The next price resistance is at 12.89. RSI (Relative Strength Index) is 62.63 on the 14-day chart, showing neutral technical sentiment.
